223 related articles for article (PubMed ID: 21308372)
1. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
Rousseau C; Devillers A; Campone M; Campion L; Ferrer L; Sagan C; Ricaud M; Bridji B; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1029-36. PubMed ID: 21308372
[TBL] [Abstract][Full Text] [Related]
2. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
5. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
[TBL] [Abstract][Full Text] [Related]
7. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
8. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
9. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
[TBL] [Abstract][Full Text] [Related]
10. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
11. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
12. Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.
García Vicente AM; Soriano Castrejón Á; León Martín A; Relea Calatayud F; Muñoz Sánchez Mdel M; Cruz Mora MÁ; Jiménez Londoño GA; Espinosa Aunión R
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1309-18. PubMed ID: 24744045
[TBL] [Abstract][Full Text] [Related]
13. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
15. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
17. Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid
de Mooij CM; Samiei S; Mitea C; Lobbes MBI; Kooreman LFS; Heuts EM; Beets-Tan RGH; van Nijnatten TJA; Smidt ML
Clin Radiol; 2022 Oct; 77(10):e732-e740. PubMed ID: 35850866
[TBL] [Abstract][Full Text] [Related]
18. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
[TBL] [Abstract][Full Text] [Related]
20. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
